Skip to main content
. 2019 Jan 30;9:3124. doi: 10.3389/fimmu.2018.03124

Figure 4.

Figure 4

Neutrophil ADCC and trogocytosis are reduced when afucosylated therapeutic antibodies are used. Afucosylated trastuzumab was compared to regularly fucosylated trastuzumab in both trogocytosis (A,B), and ADCC (C). Freshly isolated, 4 h and overnight stimulated (with G-CSF and IFNγ) neutrophils were combined with IgG opsonized SKBR3-SCR (white background) or SKBR3-CD47KD cells (gray background). Data shown are means + SEM with results from multiple experiments with donors ranging from N = 9–16. Statistical analysis was performed by paired t-test. ns, non-significant; *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001.